In draft guidance NICE does not recommend Bosulif (Pfizer) for CML
NICE has issued new preliminary draft guidance that does not recommend Bosulif (bosutinib), from Pfizer, for previously treated Chronic Myeloid Leukaemia. According to NICE, although there is evidence to suggest that bosutinib was considered clinically effective for the treatment of CML, limitations in the evidence provided by the manufacturer meant that the actual benefit compared to other treatments in terms of the estimated effect on overall survival was unclear.
The manufacturer submitted data from a clinical trial called Study 200, the trial was a single-arm study in which only a small proportion of people met the licensed indication for bosutinib.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.